Medifast Inc. (NYSE: MED) Chairman and CEO Daniel R. Chard disclosed a purchase of company common stock valued at $178,724 on March 20, 2026, according to public filings. The reported buy was executed at $10.11 per share.
This purchase comes as Medifast shares trade close to a 52-week low of $9.22, with the stock down roughly 29% over the prior six-month period. InvestingPro analysis cited in the filings describes the stock as appearing undervalued at current levels and ranks it among the more undervalued opportunities in the market.
The Form 4 filing also details a series of dispositions attributed to Chard that were made to satisfy withholding tax obligations tied to vesting restricted stock units. Specifically, the filings record disposals of 7,075 shares on March 13, 2026; 2,638 shares on March 17, 2026; and 20,095 shares on March 25, 2026. The prices for those transactions ranged from $9.59 to $10.05 and the combined value of the disposed shares was $287,284.
In addition to the purchase reported on March 20, the Form 4 shows Chard acquiring 36,968 shares and 4,827 shares on March 25, 2026, each reported with a price of $0.0 in the filing.
InvestingPro is noted as providing further context on Medifast, including a set of 10 ProTips intended for investors evaluating the name.
On the company results front, Medifast released fourth-quarter 2025 financials that included an earnings per share (EPS) shortfall and a modest revenue beat. The company reported EPS of -$1.65 for the quarter, missing the estimated -$0.45. Revenue was reported at $75.1 million, slightly above the $73.8 million consensus.
Following the results, Stephens reduced its price target for Medifast to $12 from $15 while maintaining an Equal Weight rating. The firm cited ongoing margin pressures driven by volume deleverage as the rationale for the lower target.
Company performance is further described in the filings and coverage as being affected by wider market and consumer trends: the adoption of GLP-1 treatments and a stronger consumer emphasis on value are highlighted as factors influencing client acquisition and category momentum.
Taken together, the mix of insider activity, recent financial results and analyst commentary underscores the near-term challenges the company faces as it works through margin dynamics and shifts in customer behavior.
Key details:
- Insider purchase: $178,724 on March 20, 2026, at $10.11 per share.
- Form 4 dispositions totaling $287,284 to cover withholding taxes on vesting RSUs.
- Q4 2025 EPS of -$1.65 versus an expected -$0.45; revenue $75.1M versus $73.8M estimate.
The article presents the facts reported in public filings and analyst commentary without projecting outcomes beyond the disclosed material.